Why is Beryl Drugs falling/rising?

As of 01-Jul, Beryl Drugs Ltd is experiencing a price increase, currently at Rs 22.35, reflecting a rise of 1.06 or 4.98%. The stock has shown strong performance recently, with a consecutive gain over the last five days, resulting in a 25% return during this period. Today's trading opened with a gain of 2.02%, and the stock reached an intraday high of Rs 22.35. Additionally, the stock has outperformed its sector by 5.19%. Despite a negative return of -30.55% over the past year, the stock is currently trading at a discount compared to its peers, and it has a very attractive valuation with a Return on Capital Employed (ROCE) of 11. However, the company has faced challenges, including a decline in profits by -18% over the past year, which may impact investor sentiment.
In the broader market context, Beryl Drugs has significantly outperformed the benchmark Sensex in the short term, with a 1-week return of +25.00% compared to the Sensex's +2.00%. This stark contrast highlights the stock's recent recovery phase, despite its long-term underperformance, as indicated by a -30.55% return over the past year against the Sensex's +5.31%. The stock's liquidity appears sufficient for trading, with a notable increase in delivery volume, suggesting rising investor participation. However, the company’s weak long-term fundamentals, including a low average EBIT to Interest ratio and modest growth rates in net sales and operating profit, may pose risks that could affect future performance.